❓WHAT HAPPENED: Drugmakers have reduced prices for several widely used medicines, including diabetes and blood clotting treatments.
👤WHO WAS INVOLVED: Companies like Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, and others.
📍WHEN & WHERE: Price data was released on January 30, 2026.
💬KEY QUOTE: “These are heavyweight drugs, and to see them crater in price like this is historic,” said Antonio Ciaccia, CEO of 46brooklyn Research, a Dayton, Ohio-based firm that analyzes drug pricing.
🎯IMPACT: The price cuts are expected to lower costs for patients who pay a percentage of the list price.
The costs of a number of widely used prescription drugs have seen significant price cuts since the start of 2026, bucking the long-standing trend of price increases at the beginning of a new year. Among the list price drops are popular drugs used to treat conditions like diabetes and blood clots.
President Donald J. Trump‘s sweeping drug price reforms are largely credited with driving the price drops, including Medicare‘s newly negotiated lower prices that took effect for the first time this year. A total of 20 brand-name drugs saw list-price reductions this month, ranging from 9.8 percent to 91.7 percent.
Among the notable reductions were a 43 percent cut for the blood thinner Eliquis from Pfizer and Bristol-Myers Squibb, and a 44.4 percent drop for the diabetes treatment Jardiance from Boehringer Ingelheim and Eli Lilly. “These are heavyweight drugs, and to see them crater in price like this is historic,” said Antonio Ciaccia, CEO of 46brooklyn Research, a Dayton, Ohio-based firm that analyzes drug pricing.
For patients who pay the full price or a copay based on a percentage of the list price, these reductions will mean lower costs, equating to lower prices for millions of Americans.
The National Pulse reported in December that President Trump finalized agreements with nine major U.S. and European pharmaceutical companies to lower their drug prices for American consumers, in line with the prices they charge in other countries. The agreements with Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi were announced by President Trump during an event at the White House alongside the executive leadership of the drug companies.
“As of today, 14 out of the 17 largest pharmaceutical companies… have now agreed to drastically lower drug prices for… the American people and the American patients,” Trump said during the White House even last month, adding, “This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit.”
Join Pulse+ to comment below, and receive exclusive e-mail analyses.